title: [Heart rate variability in patients with hypertension and type 2 diabetes treated with long acting calcium antagonists].
abstract: BACKGROUND
  Enhanced sympathetic activity is a potential cause of increased risk of cardiovascular complications during treatment of hypertension and type 2 diabetes.
  
  
  METHODS
  Heart rate variability (HRV) was assessed before and after 12-16 weeks of treatment with calcium antagonists in 89 patients with mild and moderate hypertension.
  
  
  RESULTS
  Changes of majority of parameters of 24 hour blood pressure monitoring were in general favorable however lowering of magnitude and rate of morning blood pressure rise was observed only in verapamil treated patients. Analysis of HRV showed that treatment with all long acting calcium antagonists under study was associated with enhancement of sympathetic activity. In supine position nifedipine treated compared with verapamil treated patients exhibited greater sympathetic activity. In upright position changes of HRV parameters characteristic for increased sympathetic activity were also more pronounced in dihydropyridine treated compared with verapamil treated patients.
  
  
  CONCLUSIONS
  Effect of calcium antagonists on parameters of HRV is negative and this should be taken into consideration when antihypertensive treatment of patients with hypertension and type 2 diabetes is selected.
authors.forename: Iu M
authors.initials: IuM
authors.lastname: Lopatin
authors.forename: D A
authors.initials: DA
authors.lastname: Kirakozov
authors.forename: M E
authors.initials: ME
authors.lastname: Statsenko
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018660:Blood Pressure Monitoring, Ambulatory; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000494:pharmacology / Q000627:therapeutic use; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D017311:Amlodipine; D014700:Verapamil; D009543:Nifedipine